TABLE 3.

Multivariate Logistic regression analysis for predictors associated with biochemical response to AA treatment in mCRPC patients after chemohormonal therapy at hormone‐sensitive stage

Variables	OR	95%CI	p Value
ADT duration (<12 vs. ≥ 12 months)	3.232	1.249–8.363	0.016
Metastatic sites (bone only vs. viscera)	0.269	0.106–0.683	0.006
SMI group (low vs. high)	3.785	1.318–10.866	0.013
PPFA/PA group (low vs. high)	0.054	0.013–0.215	<0.001

Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; CI, confidence interval; mCRPC, metastatic castration‐resistant prostate cancer; OR, odds ratio; PPFA/PA, periprostatic fat area/prostate area; SMI, skeletal muscle index.